Personalized radiation therapy combined with immunotherapy and chemotherapy for metastatic colorectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial investigates the efficacy and safety of Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) combined with the immunotherapy drug sintilimab and standard systemic therapy in patients with microsatellite stable metastatic colorectal cancer (MSS mCRC). It is a phase II, single-arm trial that assigns patients to two cohorts based on their previous treatment history. Participants will receive PULSAR in five fractions of radiation, along with sintilimab administered every three weeks, and standard systemic therapy tailored to their prior chemotherapy experiences. The study aims to analyze survival benefits, response rates, and adverse effects associated with this treatment approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient is 18-75 years old at the time of signing the informed consent form.
* ECOG performance status 0-1.
* Histopathological confirmed MSS/pMMR adenocarcinoma of the colon or rectum.
* Distant metastasis lesions are no more than 10 and all sites of disease can be safely treated based on a pre-plan.
* At least one evaluable metastatic lesion for radiotherapy and evaluation according to RECIST 1.1.
* No prior radiotherapy within 6 month.
* Previous system therapy. Patients Group Cohort A: participants who have not previously been treated with first-line chemotherapy. Cohort B: Patients with disease progression after first-line chemotherapy or stopped first-line therapy due to unacceptable toxic effects .
* Has an investigator determined life expectancy of at least 24 weeks.
* Demonstrate adequate organ function (bone marrow, liver, kidney and clotting function) within 7 days before the first administration without using blood products or hematopoietic stimulating factors.
* Non pregnant or lactating patients. Effective contraceptive methods should be used during the study and within 6 months of the last administration.
* Fully informed and willing to provide written informed consent for the trial.

Exclusion Criteria:

* History of checkpoint inhibitor therapy.
* Neutrophil\< 1.5×109/L, PLT\< 100×109/L (PLT\< 80×109/L in patients with liver metastasis), or Hb\< 90 g/L.
* TBIL \> 1.5 ULN, or TBIL \> 2.5 ULN in patients with liver metastasis. AST or ALT \> 2.5 ULN, or ALT and/or AST \> 5 ULN in patients with liver metastasis.
* Cr \> 1.5 ULN, or creatinine clearance\< 50 mL/min (calculated according to Cockcroft Gault formula).
* APTT \> 1.5 ULN, PT \> 1.5 ULN (subject to the normal value of the clinical trial research center).
* Serious electrolyte abnormalities.
* Urinary protein ≥ 2+, or 24-h urine protein ≥1.0 g/24 h.
* Uncontrolled hypertension: SBP \>140 mmHg or DBP \> 90 mmHg.
* A history of arterial thrombosis or deep vein thrombosis within 6 months; a history of bleeding or evidence of bleeding tendency within 2 months.
* A history of heart disease within 6 months.
* Uncontrolled malignant pleural effusion, ascites, or pericardial effusion.
* The presence of a clinically detectable second primary malignancy, or history of other malignancies within 5 years.
* A history of liver disease including, but not limited to, HBV infection or HBV DNA positive (≥1×104/mL), HCV infection or HCV DNA positive (≥1×103/mL),and liver cirrhosis.
* Pregnant or lactating women or women who may be pregnant have a positive pregnancy test before the first medication, or the female participants themselves and their partners who were unwilling to implement strict contraception during the study period.
* The investigator considers that the subject is not suitable to participate in this clinical study due to any clinical or laboratory abnormalities or compliance problems.
* Serious mental abnormalities.
* The diameter of brain metastasis is greater than 3 cm or the total volume is greater than 30 cc.
* Clinical or radiological evidence of spinal cord compression, or tumors within 3 mm of the spinal cord on MRI.

Where it's running

• Fudan University
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Zhen Zhang, MD,PhD
• Email: zhen_zhang@fudan.edu.cn
• Phone: 86-0204256577200

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining standard therapy with radiotherapy and toripalimab for metastatic colorectal cancer

  This study is testing if adding a new drug called toripalimab and different doses of radiation to standard treatment can help people with metastatic colorectal cancer live longer and feel better.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06525428

• Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease in Real World Practice

  This study will look at real-world safety and effectiveness of disease-modifying therapy (DMT) in adults with MCI or Alzheimer's dementia by comparing those who receive DMT in routine care to those who do not.

  Recruiting Fudan University · Shanghai, Jingan · NCT07923812

• ctDNA methylation-guided adjuvant therapy after removing colorectal liver metastases

  This trial tests whether using a blood test that detects ctDNA methylation after surgery can guide adjuvant therapy for patients who had colorectal cancer spread to the liver and were operated on with no remaining disease.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07917104

• China HEAD: a large community study on healthy aging and dementia

  This study tests whether collecting health, imaging, and biospecimen data from adults in China can help predict who will develop Alzheimer’s disease and related dementias.

  Recruiting at 30 sites Fudan University · Beijing and 29 other locations · NCT07912710

• Becotatug Vedotin plus Pucotenlimab for EGFR-positive metastatic colorectal cancer

  This study tests whether combining becotatug vedotin with pucotenlimab can shrink tumors in adults with colorectal cancer that has returned or spread after at least two prior treatments and whose tumors express EGFR.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07884188

• ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer

  This study tests whether tracking ctDNA can guide neoadjuvant immunotherapy and surgical decisions for people with dMMR/MSI-H colon cancer, using PD-1 inhibitors first and adding CTLA-4 inhibitors if ctDNA remains detectable.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07841236

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.